Trial Management Associates

Myrtle Beach, South Carolina 29572-4612

3 studies enrolling now · 15 studies all time

What they study most

COVID-19, Cardiovascular Diseases, Clostridioides Difficile Associated Disease, Diabetes Mellitus, Type 2, Diabetes, Type 2, Healthy, Influenza, Influenza, Human, Obesity, Obesity or Overweight, Obstructive Sleep Apnea, Overweight

Studies at this site

• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Recruiting now
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes — Recruiting now
• A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older — Recruiting now
• A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight — Completed
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease — Completed
• A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight — Completed
• A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes — Completed
• A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor — Completed
• A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Completed
• A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults — Completed
• A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight — Completed
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. — Completed
• A Study of LY3549492 in Healthy Weight Adult Participants — Stopped early
• A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older — Completed
• A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old — Completed